Asperger's Syndrome |
Asperger Syndrome; Asperger//'s syndrome; Asperger///'s syndrome |
Clinical Trial: Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
This study is no longer recruiting patients.
|
Purpose
OBJECTIVES: I. Identify the molecular defects responsible for primary immunodeficiency disorders. II. Explore the mutations within each syndrome to better understand the genetics of these disorders. III. Study the function of the Wiskott-Aldrich syndrome proteins (WASP). IV. Design methods to identify carriers and for prenatal diagnosis. V. Explore new avenues for therapy.
| Condition |
|---|
| X-linked agammaglobulinemia X-linked hyper IgM syndrome Wiskott-Aldrich Syndrome Leukocyte Adhesion Deficiency Syndrome |
MedlinePlus related topics: Birth Defects; Bleeding Disorders; Blood and Blood Disorders; Genetic Disorders; Immune System and Disorders; Lymphatic Diseases
Study Type: Observational
Study Design: Screening
Study start: July 1995
PROTOCOL OUTLINE: Patients are studied systematically to determine the extent of their immune deficiency and to confirm a specific diagnosis. Patients with a known immunodeficiency syndrome are studied in detail to identify the gene mutation, to assess the effect of the mutation on the gene product, and to establish cell lines for further in vitro assessment of the genetic defect. The function of Wiskott-Aldrich syndrome proteins (WASP) in hematopoietic cells is studied. Family members of patients with X-linked disorders are studied to identify carrier females.
Eligibility
Genders Eligible for Study: Both
Criteria
PROTOCOL ENTRY CRITERIA:
Primary immunodeficiency disease, e.g.: Leukocyte adhesion deficiency syndrome Wiskott-Aldrich syndrome X-linked agammaglobulinemia X-linked hyper IgM syndrome
Location Information
Washington
University of Washington School of Medicine, Seattle, Washington, 98195, United States
Hans D. Ochs, Study Chair, University of Washington
More Information
Publications
Miki H, Nonoyama S, Zhu Q, Aruffo A, Ochs HD, Takenawa T. Tyrosine kinase signaling regulates Wiskott-Aldrich syndrome protein function, which is essential for megakaryocyte differentiation. Cell Growth Differ. 1997 Feb;8(2):195-202.
Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood. 1997 Oct 1;90(7):2680-9.
Record last reviewed: October 2003
Last Updated: October 13, 2004
Record first received: October 18, 1999
ClinicalTrials.gov Identifier: NCT00004341
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


